Braftovi (encorafenib) + Erbitux (cetuximab) + mFOLFOX6 — Highmark

Initial criteria

• age ≥ 18 years
• diagnosis of metastatic colorectal cancer (ICD-10: C18, C20)
• BRAF V600E mutation as detected by an FDA-approved test
• Braftovi will be used in combination with all of the following: cetuximab AND modified FOLFOX6